How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,778 results for

Urine Uric Acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery.

Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Serum uric acid (SUA) is a novel risk factor for acute kidney injury (AKI), which adversely affects renal blood flow autoregulation, glomerular filtration rate (GFR), and promotes inflammation and angiogenesis. This pilot study investigated the effect of lowering SUA therapy on AKI, by using traditional and non-traditional markers.In this prospective, double-blind, placebo-controlled (...) , randomized pilot trial, 26 hyperuricemic patients undergoing cardiac surgery were randomized to receive rasburicase or placebo in the preoperative period.Subjects receiving rasburicase showed no difference in serum creatinine compared with the control group receiving placebo. Despite no difference in primary endpoint, the rasburicase group had less evidence of renal structural injury as reflected by urine neutrophil-associated lipocalin (uNGAL) concentrations, especially in subjects with higher SUA

2013 International urology and nephrology

122. Montmorency Cherry Juice and Uric Acid Metabolism

Montmorency Cherry Juice and Uric Acid Metabolism Montmorency Cherry Juice and Uric Acid Metabolism - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Montmorency Cherry Juice and Uric Acid Metabolism (...) to Brief Summary: Cherries have been show to possess the ability to reduce uric acid concentrations and inflammation. Tart Montmorency cherries possess a higher concentration of the plant compounds than other cherries and hence makes the expectation possible that Montmorency cherries will lower uric acid and inflammation. Condition or disease Intervention/treatment Phase Inflammation Dietary Supplement: Montmorency cherry concentrate Not Applicable Detailed Description: Plasma and urinary uric acid

2013 Clinical Trials

123. A comparison of the metabolic profiles of diabetic and non-diabetic uric acid stone formers (Full text)

. Information included patients' clinical histories, 24 hour urine collections, blood chemistry and stone analysis.Complete data were obtained from 68 patients with uric acid stones. Twenty-two patients had diabetes. There were no statistically significant differences in mean age, body mass index, or history of gout. Among diabetics, pure uric acid stones were identified in 14 patients (63%) and mixed uric acid in 8 (36%). Pure uric acid stones were more common in the diabetic cohort (63% vs. 46%, p = 0.16 (...) ). Urine pH, serum and urine uric acid levels and 24-hour urine volumes were similar in both groups. The diabetic group had an increased average oxalate excretion (424 μmol/d vs. 324 μmol/d, p = 0.003).The exact etiological basis for the higher oxalate excretion in diabetic uric acid stone formers is unclear. Whether this is a metabolic feature of diabetes, due to dietary indiscretion or the iatrogenic consequence of dietary advice requires further investigation.

2013 Canadian Urological Association Journal PubMed

124. Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. (Full text)

population from 642 American twins and siblings of European and Hispanic ancestry. Transcriptional activity of promoter variants was estimated in luciferase reporter plasmids transfected into HEK-293 cells and mIMCD3 cells. In the primary Chinese population, we found that carriers of the GCC haplotype had higher plasma uric acid, and three promoter variants were associated with plasma uric acid. UMOD promoter variants displayed reciprocal effects on urine uric acid excretion and plasma uric acid (...) Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Uromodulin (UMOD) genetic variants cause familial juvenile hyperuricemic nephropathy, characterized by hyperuricemia with decreased renal excretion of UMOD and uric acid, suggesting a role for UMOD in the regulation of plasma uric acid. To determine this, we screened common variants across the UMOD locus in one community-based Chinese population of 1000 individuals and the other

2013 Kidney International PubMed

125. Understanding the Urine Electrolyte Profile of the Individual Renal Unit

, oxalate, potassium, magnesium, phosphate, uric acid, and urate. When an abnormality is detected on a 24-hour urine collection the assumption is that this is due to a global metabolic defect present in both kidneys. However, this may not be the case. It is possible there could be a relative imbalance with both kidneys having a defect, but to different degrees (or different defects in one or multiple electrolytes). It is also possible that one kidney has a dominant defect, but the contralateral kidney (...) Understanding the Urine Electrolyte Profile of the Individual Renal Unit Understanding the Urine Electrolyte Profile of the Individual Renal Unit - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2016 Clinical Trials

126. Porous extraction paddle: a solid phase extraction technique for studying the urine metabolome (Full text)

from uric acid to peptides.The PEP allows the user to extract a large liquid sample in a jar simply by turning on a motor. The technique will be helpful in conducting metabolomics and xenobiotic exposome studies of urine, encouraging the extraction of large volumes to set up a convenient repository sample (e.g. 2 g of exposed adsorbent in a cryovial) for shipment and re-analysis in various ways in the future, including scaled-up isolation of unknown chemicals for identification. Copyright © 2016 (...) Porous extraction paddle: a solid phase extraction technique for studying the urine metabolome A method was needed to accomplish solid-phase extraction of a large urine volume in a convenient way where resources are limited, towards a goal of metabolome and xenobiotic exposome analysis at another, distant location.A porous extraction paddle (PEP) was set up, comprising a porous nylon bag containing extraction particles that is flattened and immobilized between two stainless steel meshes

2016 Rapid communications in mass spectrometry : RCM PubMed

127. THE ROLE OF LACTIC ACID IN THE REDUCED EXCRETION OF URIC ACID IN TOXEMIA OF PREGNANCY (Full text)

-Eclampsia urine Pregnancy Uric Acid blood LACTATES/pharmacology PREGNANCY TOXEMIAS/urine URIC ACID/blood 1960 10 1 1960 10 1 0 1 1960 10 1 0 0 ppublish 13711188 10.1172/JCI104172 PMC441887 Proc Soc Exp Biol Med. 1957 Dec;96(3):809-13 13505867 J Clin Invest. 1940 May;19(3):525-35 16694770 J Obstet Gynaecol Br Emp. 1953 Jun;60(3):335-44 13061996 Lancet. 1955 Feb 12;268(6859):323-5 13234369 Bull N Y Acad Med. 1958 May;34(5):287-96 13523299 Am J Obstet Gynecol. 1957 Mar;73(3):492-506 13402821 J Clin Invest (...) THE ROLE OF LACTIC ACID IN THE REDUCED EXCRETION OF URIC ACID IN TOXEMIA OF PREGNANCY 13711188 1998 11 01 2018 11 30 0021-9738 39 1960 Oct The Journal of clinical investigation J. Clin. Invest. The role of lactic acid in the reduced excretion of uric acid in toxemia of pregnancy. 1526-32 HANDLER J S JS eng Journal Article United States J Clin Invest 7802877 0021-9738 0 Lactates 268B43MJ25 Uric Acid 33X04XA5AT Lactic Acid OM Body Fluids Female Humans Lactates pharmacology Lactic Acid Pre

1960 Journal of Clinical Investigation PubMed

128. Urinary calcium and uric acid excretion in children with vesicoureteral reflux. (PubMed)

healthy children without any history of reflux or urinary tract infection (30 boys, 80 girls; age range 2 months to 12 years). Fasting urine was analyzed for the calcium/creatinine (Ca/Cr) and uric acid/creatinine (UA/Cr) ratios. Hypercalciuria was more frequently diagnosed in the VUR patients than in the control group (21.3 vs. 3.6%; P = 0.0001). Significant differences between the two groups were also found for the mean Ca/Cr and UA/Cr ratios (P = 0.0001 and P = 0.0001, respectively). No differences (...) Urinary calcium and uric acid excretion in children with vesicoureteral reflux. Urolithiasis is relatively common in children, and identifiable predisposing factors for stone formation, including metabolic and structural derangements, can be established in most cases. Vesicoureteral reflux (VUR) is a common cause of kidney stone formation. The pathophysiological mechanism of urolithiasis in reflux is related to urinary tract infection and urinary stasis, both of which promote urinary crystal

2012 Pediatric Nephrology

129. Uric Acid Nephrolithiasis

Acid Nephrolithiasis Aka: Uric Acid Nephrolithiasis , Urate Stones , Hyperuricosuria , Uric Acid Calculi From Related Chapters II. Epidemiology Represents 10% of s III. Evaluation See IV. Types Pure Uric Acid Calculi Mixed calcium and Uric Acid Calculi V. Causes Primary cause Acidic urine (pH <5.5) Other causes (confers 2 fold risk of calculi) Excessive dietary purine intake (meats) End Ileostomy Results in impaired ammonia and citrate excretion Results in lower pH and increased urinary ammonia (...) Increased crystallization VI. Labs AM spot urine for and Crystaluria stones form in acidic urine VII. Imaging Non-contrast XRay Pure Uric Acid Calculi are radiolucent May be visualized if mixed calcium and VIII. Management: Prevention of Uric Acid stone recurrence ral Restrict dietary intake of and protein Maintain : over 2.5 liters per day Alkalinize urine (especially if is low, acidic) Maintain >5.5 (6.5 - 7.0 preferred) Citrate 10-20 mEq orally three times daily with meals 500 mg, two tablets daily

2015 FP Notebook

130. Uric Acid

) These images are a random sampling from a Bing search on the term "Uric Acid." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Uric Acid (C0041980) Definition (NCI_NCI-GLOSS) A waste product left over from normal chemical processes in the body and found in the urine and blood. Abnormal buildup of uric acid in the body may cause a condition called gout. Increased levels of uric acid in the blood and urine can be a side (...) Uric Acid Uric Acid Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Uric Acid Uric Acid Aka: Uric Acid II. Physiology Uric Acid

2015 FP Notebook

131. The Relationship Between Uric Acid and Inflammatory Markers

and urine tests, and an electrocardiogram. Participants will be divided into two groups based on the existing amount of uric acid in their blood. Within 7 days of the screening visit, participants will have a full-day study visit with a magnetic resonance imaging scan, followed by a high-fat meal and further blood samples collected over the following 8 hours. At least 2 days after the first study visit, participants will have the second study visit, which will require a 2-night stay at the National (...) Institutes of Health. Participants will have a metabolism test, and will receive the following infusions based on the groups they were assigned to at the screening visit. Group A (low uric acid) will receive either uric acid or a placebo. Group B (moderate to high uric acid) will receive either Rasburicase (a drug that reduces the amount of uric acid in the blood) or a placebo. After the infusions and related blood tests, participants will have a high-fat meal with further blood and urine samples

2011 Clinical Trials

132. Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals

Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects (...) of Green Tea on Level of Serum Uric Acid in Healthy Individuals The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01363869 Recruitment Status : Completed First Posted : June 2, 2011 Last Update Posted : April 25, 2013 Sponsor: Chiang Mai University Information provided by (Responsible Party): Kanon

2011 Clinical Trials

133. Plasma uric acid and spironolactone response in healthy subjects. (PubMed)

Sodium AYI8EX34EU Creatinine RWP5GA015D Potassium IM Biological Availability Canrenone analysis Creatinine metabolism Humans Potassium urine Sodium urine Spironolactone administration & dosage metabolism pharmacology Tablets Uric Acid blood 1977 4 1 1977 4 1 0 1 1977 4 1 0 0 ppublish 861142 PMC1429001 J Pharmacol Exp Ther. 1962 Mar;135:312-6 13899372 Br J Clin Pharmacol. 1975 Jun;2(3):271-6 1234508 Br J Clin Pharmacol. 1975 Aug;2(4):361-2 1233997 Clin Pharmacol Ther. 1975 Oct;18(4):391-400 1100306 (...) Plasma uric acid and spironolactone response in healthy subjects. 861142 1977 07 29 2018 11 13 0306-5251 4 2 1977 Apr British journal of clinical pharmacology Br J Clin Pharmacol Plasma uric acid and spironolactone response in healthy subjects. 247-9 Ramsay L E LE Shelton J R JR Harrison I R IR eng Clinical Trial Journal Article Randomized Controlled Trial England Br J Clin Pharmacol 7503323 0306-5251 0 Tablets 268B43MJ25 Uric Acid 27O7W4T232 Spironolactone 78O20X9J0U Canrenone 9NEZ333N27

1977 British journal of clinical pharmacology

134. A relationship between plasma uric acid concentration and the apparent response to frusemide in normal subjects. (Full text)

7LXU5N7ZO5 Furosemide 9NEZ333N27 Sodium RWP5GA015D Potassium IM Adult Diuresis drug effects Furosemide pharmacology Humans Male Potassium urine Sodium urine Time Factors Uric Acid blood 1975 8 1 1975 8 1 0 1 1975 8 1 0 0 ppublish 1233997 PMC1402605 Clin Chem. 1967 Jan;13(1):12-8 6016591 Br J Clin Pharmacol. 1975 Jun;2(3):271-6 1234508 (...) A relationship between plasma uric acid concentration and the apparent response to frusemide in normal subjects. 1233997 1976 12 30 2018 11 13 0306-5251 2 4 1975 Aug British journal of clinical pharmacology Br J Clin Pharmacol A relationship between plasma uric acid concentration and the apparent response to frusemide in normal subjects. 361-2 Ramsay L E LE Tidd M J MJ Auty R M RM Levine D D Branch R A RA eng Journal Article England Br J Clin Pharmacol 7503323 0306-5251 268B43MJ25 Uric Acid

1975 British journal of clinical pharmacology PubMed

135. Factors inhibiting the excretion of uric acid. (Full text)

Factors inhibiting the excretion of uric acid. 5937678 1966 08 29 2018 11 13 0035-9157 59 4 1966 Apr Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Factors inhibiting the excretion of uric acid. 310-3 Scott J T JT eng Journal Article England Proc R Soc Med 7505890 0035-9157 268B43MJ25 Uric Acid IM Blood Gout etiology Humans Uric Acid metabolism Urine 1966 4 1 1966 4 1 0 1 1966 4 1 0 0 ppublish 5937678 PMC1900627 J Chronic Dis. 1961 Nov;14:495-506 14483759 Metabolism. 1965 Feb

1966 Proceedings of the Royal Society of Medicine PubMed

136. Urinary hydrogen ion excretion in patients with uric acid calculi. (Full text)

Urinary hydrogen ion excretion in patients with uric acid calculi. 5937679 1966 08 29 2018 11 13 0035-9157 59 4 1966 Apr Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Urinary hydrogen ion excretion in patients with uric acid calculi. 313-5 Wrong O O eng Journal Article England Proc R Soc Med 7505890 0035-9157 7664-41-7 Ammonia IM Ammonia metabolism Humans Hydrogen-Ion Concentration Urinary Calculi etiology Urine 1966 4 1 1966 4 1 0 1 1966 4 1 0 0 ppublish 5937679 PMC1900628 Q

1966 Proceedings of the Royal Society of Medicine PubMed

137. Effect of atromid and its components on uric acid excretion and on gout. (Full text)

Humans Male Uric Acid Uricosuric Agents therapeutic use Urine 1965 11 1 1965 11 1 0 1 1965 11 1 0 0 ppublish 5855251 PMC1010409 J Atheroscler Res. 1963 Sep-Dec;3:475-81 14100888 J Atheroscler Res. 1963 Sep-Dec;3:554-60 14100898 J Clin Invest. 1959 Aug;38(8):1298-315 13673086 J Lab Clin Med. 1959 Dec;54:903-13 14416793 Proc Soc Exp Biol Med. 1950 May;74(1):148-51 15430417 J Atheroscler Res. 1963 Sep-Dec;3:593-616 14104298 Lancet. 1962 Jun 23;1(7243):1321-3 14481816 Ann Rheum Dis. 1957 Dec;16(4):425-37 (...) Effect of atromid and its components on uric acid excretion and on gout. 5855251 1966 03 27 2018 11 13 0003-4967 24 6 1965 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Effect of atromid and its components on uric acid excretion and on gout. 572-5 Trevaks G G Lovell R R RR eng Journal Article England Ann Rheum Dis 0372355 0003-4967 0 Butyrates 0 Uricosuric Agents 268B43MJ25 Uric Acid C24W7J5D5R Androsterone IM Adult Androsterone therapeutic use Butyrates therapeutic use Female Gout

1965 Annals of the Rheumatic Diseases PubMed

138. Effects of Allopurinol on Gouty and Non-Gouty Uric Acid Nephropathy (Full text)

Sulfinpyrazone IM Allopurinol therapeutic use Blood Urea Nitrogen Enzyme Therapy Female Gout complications Humans Kidney Calculi drug therapy Kidney Diseases drug therapy Male Salicylates therapeutic use Sulfinpyrazone therapeutic use Uric Acid blood urine Xanthine Oxidase 1966 11 1 1966 11 1 0 1 1966 11 1 0 0 ppublish 5958697 PMC2453415 10.1136/ard.25.Suppl_6.673 (...) Effects of Allopurinol on Gouty and Non-Gouty Uric Acid Nephropathy 5958697 1967 04 13 2018 11 30 0003-4967 25 6 Suppl 1966 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Effects of allopurinol on gouty and non-gouty uric acid nephropathy. 673-80 10.1136/ard.25.Suppl_6.673 Ogryzlo M A MA Urowitz M B MB Weber H M HM Houpt J B JB eng Journal Article England Ann Rheum Dis 0372355 0003-4967 0 Salicylates 268B43MJ25 Uric Acid 63CZ7GJN5I Allopurinol EC 1.17.3.2 Xanthine Oxidase V6OFU47K3W

1966 Annals of the Rheumatic Diseases PubMed

139. Allopurinol in the Prophylaxis of Uric Acid Stones (Full text)

complications Humans Hydrogen-Ion Concentration Kidney Calculi drug therapy Male Uric Acid urine Xanthine Oxidase 1966 11 1 1966 11 1 0 1 1966 11 1 0 0 ppublish 5958700 PMC2453421 10.1136/ard.25.Suppl_6.691 (...) Allopurinol in the Prophylaxis of Uric Acid Stones 5958700 1967 04 13 2018 11 30 0003-4967 25 6 Suppl 1966 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Allopurinol in the prophylaxis of uric acid stones. 691-3 10.1136/ard.25.Suppl_6.691 de Vries A A Frank M M Liberman U A UA Sperling O O eng Journal Article England Ann Rheum Dis 0372355 0003-4967 268B43MJ25 Uric Acid 63CZ7GJN5I Allopurinol EC 1.17.3.2 Xanthine Oxidase IM Allopurinol therapeutic use Enzyme Therapy Female Gout

1966 Annals of the Rheumatic Diseases PubMed

140. The Treatment of Gout and Disorders of Uric Acid Metabolism with Allopurinol (Full text)

concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function. Oxypurine excretion increased concomitantly with the fall in urine uric acid. The agent is particularly valuable in the management of problems of gout with azotemia, acute uric acid nephropathy and uric acid urolithiasis. The minor side effects, clinical indications and theoretical complications are discussed. (...) The Treatment of Gout and Disorders of Uric Acid Metabolism with Allopurinol Allopurinol (4-hydroxypyrazolo (3,4-d)-pyrimidine) is a potent xanthine oxidase inhibitor which inhibits the oxidation of naturally occurring oxypurines, thus decreasing uric acid formation. The clinical and metabolic effects of this agent were studied in 80 subjects with primary and secondary gout and other disorders of uric acid metabolism. Allopurinol has been universally successful in lowering the serum uric acid

1966 Canadian Medical Association Journal PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>